Support for you and your patients with IBS-D

The resources below include information about dosing, insurance requirements,* and the science behind XIFAXAN. You’ll also find materials to share with your patients to help them understand treatment with XIFAXAN and keep track of their IBS-D symptoms.

XIFAXAN FIRST Dosing Flashcard

Find dosing information for IBS-D and overt HE indications on this at-a-glance card.

Bacterial Imbalance Flashcard

Understand a cause affecting many IBS-D patients and how XIFAXAN may work to relieve symptoms.

Prior Authorization (PA) Considerations Handout

Keep easy-to-follow directions on-hand to help make PA submissions simple for XIFAXAN. Includes both IBS-D and HE indications.

Letter of Medical Necessity

A standard form for a patient‐specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.

Tier Exception Request

A Tier Exception request to reduce the cost-share of a medication. Follows submission of a PA or Utilization Management request.

IBS-D = irritable bowel syndrome with diarrhea.

HE = hepatic encephalopathy.

*Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

XIFAXAN Patient Brochure

Keep patients informed about what it means to have and treat IBS-D with XIFAXAN.

Food Diary & Symptom Tracker

Ask patients to track diet and IBS-D symptoms to aid your in-office discussions.

Instant Savings Card

Available for eligible, commercially insured patients.

IBS-D = irritable bowel syndrome with diarrhea.

HE = hepatic encephalopathy.

*Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.

†Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.